Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,721.70
(
0.33%
)
US TECH 100
24,126.54
(
0.46%
)
Dow Jones
47,071.06
(
0.27%
)
Brent Oil
99.74
(
1.46%
)
Bitcoin
74,164.07
(
-0.91%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: floblu14 post# 83528

Monday, 09/14/2009 11:29:52 PM

Monday, September 14, 2009 11:29:52 PM

Post# of 257251
MNTA – That MYL planned to submit a Copaxone ANDA based on the product from NATCO, its Indian partner, has been known for more than a year (#msg-29902618). Thus, today’s news that MYL submitted an ANDA and the FDA decided to review it is not especially consequential for MNTA investors.

If the FDA ended up approving MYL’s Copaxone ANDA, that would of course be consequential.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now